We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Gilead Sciences (GILD - Free Report) closed at $61.55 in the latest trading session, marking a -0.92% move from the prior day. This change lagged the S&P 500's 0.59% gain on the day. Meanwhile, the Dow gained 0.15%, and the Nasdaq, a tech-heavy index, lost 0.02%.
Heading into today, shares of the HIV and hepatitis C drugmaker had gained 2.66% over the past month, lagging the Medical sector's gain of 8.26% and the S&P 500's gain of 7.25% in that time.
Wall Street will be looking for positivity from Gilead Sciences as it approaches its next earnings report date. This is expected to be August 2, 2022. On that day, Gilead Sciences is projected to report earnings of $1.53 per share, which would represent a year-over-year decline of 18.18%. Meanwhile, our latest consensus estimate is calling for revenue of $5.88 billion, down 5.36% from the prior-year quarter.
GILD's full-year Zacks Consensus Estimates are calling for earnings of $6.59 per share and revenue of $24.65 billion. These results would represent year-over-year changes of -9.48% and -9.73%, respectively.
Any recent changes to analyst estimates for Gilead Sciences should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.01% higher. Gilead Sciences currently has a Zacks Rank of #3 (Hold).
In terms of valuation, Gilead Sciences is currently trading at a Forward P/E ratio of 9.42. This valuation marks a discount compared to its industry's average Forward P/E of 22.63.
Also, we should mention that GILD has a PEG ratio of 0.63. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. GILD's industry had an average PEG ratio of 1.18 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 82, putting it in the top 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Gilead Sciences (GILD - Free Report) closed at $61.55 in the latest trading session, marking a -0.92% move from the prior day. This change lagged the S&P 500's 0.59% gain on the day. Meanwhile, the Dow gained 0.15%, and the Nasdaq, a tech-heavy index, lost 0.02%.
Heading into today, shares of the HIV and hepatitis C drugmaker had gained 2.66% over the past month, lagging the Medical sector's gain of 8.26% and the S&P 500's gain of 7.25% in that time.
Wall Street will be looking for positivity from Gilead Sciences as it approaches its next earnings report date. This is expected to be August 2, 2022. On that day, Gilead Sciences is projected to report earnings of $1.53 per share, which would represent a year-over-year decline of 18.18%. Meanwhile, our latest consensus estimate is calling for revenue of $5.88 billion, down 5.36% from the prior-year quarter.
GILD's full-year Zacks Consensus Estimates are calling for earnings of $6.59 per share and revenue of $24.65 billion. These results would represent year-over-year changes of -9.48% and -9.73%, respectively.
Any recent changes to analyst estimates for Gilead Sciences should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.01% higher. Gilead Sciences currently has a Zacks Rank of #3 (Hold).
In terms of valuation, Gilead Sciences is currently trading at a Forward P/E ratio of 9.42. This valuation marks a discount compared to its industry's average Forward P/E of 22.63.
Also, we should mention that GILD has a PEG ratio of 0.63. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. GILD's industry had an average PEG ratio of 1.18 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 82, putting it in the top 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.